Immune Activation With Modified Citrus Pectin in Cancer Models
Immune Activation With Modified Citrus Pectin in Cancer Models
Ramachandran and colleagues investigated how modified citrus pectin (MCP), a complex carbohydrate derived from citrus fruit, influences immune cell activity relevant to cancer. Specifically, the study examined whether MCP could stimulate human immune cells—including T helper, T cytotoxic, B cells, and natural killer (NK) cells—and whether this immune activation translated into enhanced NK cell–mediated killing of leukemia cells in laboratory models.
In the study, immune cells isolated from healthy human donors were exposed to MCP in vitro, and researchers measured changes in immune cell populations and function. They then assessed whether MCP-treated NK cells showed increased cytotoxicity against K562 cells, a standard laboratory model of chronic myeloid leukemia used to evaluate NK cell activity.
The investigators found that MCP exposure led to increased markers of activation across multiple immune cell types, including enhanced proliferation and functional activation of NK cells. Importantly, MCP-treated NK cells demonstrated greater cytotoxic activity against K562 leukemia cells compared with untreated controls, indicating that MCP may bolster innate anti-tumor immune responses under experimental conditions.
Although this was a laboratory study and cannot be directly applied to patients, it provides valuable insight into how MCP interacts with the immune system at a cellular level. These findings support further investigation into whether dietary or supplemental MCP could modulate immune function in clinical cancer care, particularly in strategies aimed at enhancing anti-tumor immunity.
Reference:
Ramachandran C, Wilk BJ, Hotchkiss A, Chau H, Eliaz I, Melnick SJ. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK) cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complement Altern Med. 2011;11:59. doi:10.1186/1472-6882-11-59. PMID: 21816083; PMCID: PMC3161912.
